1-2 of 2
Hans Erik Johnsen, MD,DMSC
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Efstathios Kastritis, MD, Xavier Leleu, Bertrand Arnulf, MD, Elena Zamagni, María Teresa Cibeira, MD, Fiona Kwok, FRACP, FRCPA, MBBS, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Roman Hajek, MD, Philippe Moreau, Arnaud Jaccard, MD PhD, Stefan Schönland, MD, Robin Filshie, PhD FRACP FRCPA, Emmanuelle Nicolas-Virelizier, MD, Bradley Augustson, Maria-Victoria Mateos, MD PhD, Ashutosh Wechalekar, MD FRCPath, Eric Hachulla, MD PhD, Paolo Milani, MD, Meletios A Dimopoulos, Jean-Paul Fermand, Andrea Foli, MD, Maria Gavriatopoulou, Antonio Palumbo, MD, Pieter Sonneveld, MD PhD, Hans Erik Johnsen, MD DMSc, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD
Journal: Blood
Blood (2016) 128 (22): 646.
https://doi.org/10.1182/blood.V128.22.646.646
Published: 2016
Journal Articles

A Novel Chemo Sensitivity Index for Melphalan Based on Gene Expression Profiling (GEP).

Jesper O. Dahlgaard, PhD, Karen Dybkaer, PhD, Hans Erik Johnsen, MD,DMSC, Steen Knudsen, PhD
Journal: Blood
Blood (2007) 110 (11): 4191.
https://doi.org/10.1182/blood.V110.11.4191.4191
Published: 2007